-----BEGIN PRIVACY-ENHANCED MESSAGE----- Proc-Type: 2001,MIC-CLEAR Originator-Name: webmaster@www.sec.gov Originator-Key-Asymmetric: MFgwCgYEVQgBAQICAf8DSgAwRwJAW2sNKK9AVtBzYZmr6aGjlWyK3XmZv3dTINen TWSM7vrzLADbmYQaionwg5sDW3P6oaM5D3tdezXMm7z1T+B+twIDAQAB MIC-Info: RSA-MD5,RSA, IhybJ3xJK3tjrT3pr7cyxLIebBKQC5/EcMTZbM+rXnWFg5+Z/vjZ86/+jEHSIKT1 hPf1MMY5AM4vF81OnuEwQQ== 0000875620-96-000027.txt : 19960816 0000875620-96-000027.hdr.sgml : 19960816 ACCESSION NUMBER: 0000875620-96-000027 CONFORMED SUBMISSION TYPE: NT 10-Q PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 19960630 FILED AS OF DATE: 19960814 SROS: NASD FILER: COMPANY DATA: COMPANY CONFORMED NAME: MERIS LABORATORIES INC CENTRAL INDEX KEY: 0000875620 STANDARD INDUSTRIAL CLASSIFICATION: SERVICES-MEDICAL LABORATORIES [8071] IRS NUMBER: 770274078 STATE OF INCORPORATION: CA FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: NT 10-Q SEC ACT: 1934 Act SEC FILE NUMBER: 000-19360 FILM NUMBER: 96615438 BUSINESS ADDRESS: STREET 1: 2890 ZANKER RD CITY: SAN JOSE STATE: CA ZIP: 95134 BUSINESS PHONE: 4084349200 MAIL ADDRESS: STREET 1: 2890 ZANKER RD CITY: SAN JOSE STATE: CA ZIP: 95134 NT 10-Q 1 NOTIFICATION OF LATE FILING FOR FORM 10-Q 6/30/96 ----------------------------- UNITED STATES OMB APPROVAL SECURITIES AND EXCHANGE COMMISSION ----------------------------- Washington, D.C. 20549 OMB Number: 3235-0058 Expires: May 31, 1997 Estimated average burden FORM 12b-25 hours per response ..... 2.50 ----------------------------- NOTIFICATION OF LATE FILING SEC FILE NUMBER ----------------------------- CUSIP NUMBER ----------------------------- (Check One): |_| Form 10-K |_| Form 20-F |_| Form 11-K |X| Form 10-Q |_| Form N-SAR For Period Ended: June 30, 1996 -------------------------------- [ ] Transition Report on Form 10-K [ ] Transition Report on Form 20-F [ ] Transition Report on Form 11-K [ ] Transition Report on Form 10-Q [ ] Transition Report on Form N-SAR For the Transition Period Ended: --------------------------- Nothing in this form shall be construed to imply that the Commission has verified any information contained herein. If the notification relates to a portion of the filing checked above, identify the Item(s) to which the notification relates: PART I -- REGISTRANT INFORMATION MERIS LABORATORIES, INC. - -------------------------------------------------------------------------------- Full Name of Registrant N/A - -------------------------------------------------------------------------------- Former Name if Applicable 2890 ZANKER ROAD - -------------------------------------------------------------------------------- Address of Principal Executive Office (Street and Number) SAN JOSE, CALIFORNIA 95134 - -------------------------------------------------------------------------------- City, State and Zip Code 1 PART II -- RULES 12b-25(b) AND (c) If the subject report could not be filed without unreasonable effort or expense and the registrant seeks relief pursuant to Rule 12b-25(b), the following should be completed. (Check box if appropriate) |X| | (a) The reasons described in reasonable detail in Part III of this | form could not be eliminated without unreasonable effort or | expense; | |X| | (b) The subject annual report, semi-annual report, transition | report on Form 10-K, Form 20-F, Form 11-K or Form N-SAR, or | portion thereof, will be filed on or before the fifteenth calendar | day following the prescribed due date; or the calendar day | following the prescribed due date; and subject quarterly report | of transition report on Form 10-Q, or portion thereof will be | filed on or before the fifth calendar day following the | prescribed due date; and | |_| | (c) The accountant's statement or other exhibit required by Rule | 12b-25(c) has been attached if applicable. PART III -- NARRATIVE State below in reasonable detail the reasons why Forms 10-K, 20-F, 11-K, 10-Q, N-SAR, or the transition report or portion thereof, could not be filed within the prescribed time period. (Attach Extra Sheets if Needed) The Registrant has not been able to finalize its financial statements, including matters pending with respect to the Company's line of credit and debenture agreements, related to the Quarterly Report on Form 10-Q for the period ended June 30, 1996 within the required due date. PART IV--OTHER INFORMATION (1) Name and telephone number of person to contact in regard to this notification Thurman Jordan 408 434-9200 ext.3722 --------------------------------------------------------------------------- (Name) (Area Code) (Telephone Number) 2 (2) Have all other periodic reports required under Section 13 or 15(d) of the Securities Exchange Act of 1934 or Section 30 of the Investment Company Act of 1940 during the preceding 12 months or for such shorter period that the registrant was required to file such report(s) been filed? If answer is no, identify report(s). |X| Yes |_| No --------------------------------------------------------------------------- (3) Is it anticipated that any significant change in results of operations from the corresponding period for the last fiscal year will be reflected by the earnings statements to be included in the subject report or portion thereof? |X| Yes |_| No If so, attach an explanation of the anticipated change, both narratively and quantitatively, and, if appropriate, state the reasons why a reasonable estimate of the results cannot be made. (See Exhibit A) ================================================================================ Meris Laboratories, Inc. -------------------------------------------------------------- (Name of Registrant as Specified in Charter) has caused this notification to be signed on its behalf by the undersigned hereunto duly authorized. Date: August 14, 1996 By: /s/ Thurman Jordan -------------------- ----------------------------- Thurman Jordan Senior Vice President - Finance (Duly authorized Officer and Principal Financial and Accounting Officer) INSTRUCTION: The form may be signed by an executive officer of the registrant or by any other duly authorized representative. The name and title of the person signing the form shall be typed or printed beneath the signature. If the statement is signed on behalf of the registrant by an authorized representative (other than an executive officer), evidence of the representative's authority to sign on behalf of the registrant shall be filed with the form. - ----------------------------- ATTENTION ---------------------------------------- Intentional misstatements or omissions of fact constitute Federal Criminal Violations (See 18 U.S.C. 1001). - -------------------------------------------------------------------------------- 3 EXHIBIT A FOR PART IV - OTHER INFORMATION (3) The Registrant believes its continuing losses result from increased competition in the clinical laboratory industry, decreased testing volume levels, further reductions in reimbursement rates including reductions effected by Medicare, billing and accounts receivable issues, and on-going litigation. The Registrant expects to report net losses of approximately $4.9 million and $6.0 million for the three and six month periods ended June 30, 1996, respectively, as compared to $3.7 million and $3.3 million for the three and six month period ended June 30, 1995, respectively. The Registrant is not able to file its Quarterly Report on Form 10-Q for the period ended June 30, 1996 on August 14, 1996 and anticipates to file such Report on or before August 19, 1996. 4 -----END PRIVACY-ENHANCED MESSAGE-----